Since the activity of AMPK is reduced in obesity and NAFLD9,14,15, increasing AMPK activity has been suggested as an attractive therapeutic option for treating metabolic disorders, including NAFLD. Here, PRKAB1 is linked to metabolic dysfunction-associated steatotic liver disease.